WallStSmart

Abbott Laboratories (ABT)vsVistra Corp. (VST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 154% more annual revenue ($45.13B vs $17.74B). ABT leads profitability with a 13.9% profit margin vs 5.3%. ABT appears more attractively valued with a PEG of 1.29. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

VST

Buy

53

out of 100

Grade: C-

Growth: 3.3Profit: 6.0Value: 3.3Quality: 2.5
Piotroski: 2/9Altman Z: 0.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$87.55

Current Price

$84.32

$3.23 discount

UndervaluedFair: $87.55Overvalued
VSTSignificantly Overvalued (-52.8%)

Margin of Safety

-52.8%

Fair Value

$101.40

Current Price

$147.72

$46.32 premium

UndervaluedFair: $101.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

VST1 strengths · Avg: 9.0/10
Market CapQuality
$52.12B9/10

Large-cap with strong market position

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

VST4 concerns · Avg: 3.0/10
Price/BookValuation
19.1x4/10

Trading at 19.1x book value

Profit MarginProfitability
5.3%3/10

5.3% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
70.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : VST

The strongest argument for VST centers on Market Cap. Revenue growth of 13.6% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : VST

The primary concerns for VST are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 70.6x leaves little room for execution misses. Debt-to-equity of 3.36 is elevated, increasing financial risk.

Key Dynamics to Monitor

VST carries more volatility with a beta of 1.45 — expect wider price swings.

VST is growing revenue faster at 13.6% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Vistra Corp.

UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA

Vistra Corp. The company is headquartered in Irving, Texas.

Visit Website →

Want to dig deeper into these stocks?